LIXTE Biotechnology, a publicly traded company in the U.S., has launched a cryptocurrency reserve strategy, planning to allocate 25% of its funds to BTC

ChainCatcher reminds readers to view blockchain rationally, enhance risk awareness, and be cautious of various virtual token issuances and speculations. All content on this site is solely market information or related party opinions, and does not constitute any form of investment advice. If you find sensitive information in the content, please click “Report”, and we will handle it promptly.